Shire's Vyvanse performs well in BED
This article was originally published in Scrip
Executive Summary
Shire's shares opened up 2% on 5 November at £28.77 on the London Stock Exchange following positive top-line Phase III results for its approved ADHD drug Vyvanse (lisdexamfetamine dimesylate) in binge eating disorder (BED). The company said it would file for US approval in the new indication by the third quarter of 2014 on the back of the new data, which came earlier than expected.